P
TXG icon

&Partners’s 10x Genomics TXG Stock Holding History

&Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Sell
7,172
-6,448
-47% -$169K ﹤0.01% 2193
2026
Q1 		$289K Buy
13,620
+281
+2% +$5.62K ﹤0.01% 2019
2025
Q4 		$218K Buy
+13,339
New +$202K ﹤0.01% 2098

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

&Partners's TXG Position: Q2 2026 in Review

&Partners reduced its 10x Genomics (TXG) stake by 47% in Q2 2026, selling an estimated $169K and leaving 7,172 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #2193.

&Partners first reported a position in TXG in Q4 2025 and has held it in 3 quarters since. The position peaked at $289K in Q1 2026. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • &Partners held 7,172 shares of 10x Genomics worth $275K as of Q2 2026.
  • &Partners sold 6,448 10x Genomics shares in Q2 2026, an estimated $169K.
  • 10x Genomics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2193 holding.
  • &Partners first reported a position in 10x Genomics in Q4 2025 and has held it in 3 quarters since.
  • &Partners's 10x Genomics position peaked at $289K in Q1 2026.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.